Foresite Capital Management III, LLC Buys ORIC Pharmaceuticals Inc, Blueprint Medicines Corp, CymaBay Therapeutics Inc, Sells Immunomedics Inc, Aerie Pharmaceuticals Inc, Biohaven Pharmaceutical Holding Co

• New Purchases: ORIC, CBAY,
• Added Positions: BPMC, EPZM, MYOK,
• Sold Out: IMMU, AERI, BHVN,

For the details of Foresite Capital Management III, LLC's stock buys and sells, go to https://www.gurufocus.com/guru/foresite+capital+management+iii%2C+llc/current-portfolio/portfolio

1. MyoKardia Inc (MYOK) - 399,360 shares, 34.31% of the total portfolio. Shares added by 3.61%
2. Blueprint Medicines Corp (BPMC) - 249,598 shares, 17.31% of the total portfolio. Shares added by 46.91%
3. ORIC Pharmaceuticals Inc (ORIC) - 496,893 shares, 14.90% of the total portfolio. New Position
4. Epizyme Inc (EPZM) - 998,278 shares, 14.26% of the total portfolio. Shares added by 39.85%
5. Natera Inc (NTRA) - 208,768 shares, 9.26% of the total portfolio.

Foresite Capital Management III, LLC initiated holding in ORIC Pharmaceuticals Inc. The purchase prices were between $25.68 and $38.12, with an estimated average price of $31.84. The stock is now traded at around $25.51. The impact to a portfolio due to this purchase was 14.9%. The holding were 496,893 shares as of .

Foresite Capital Management III, LLC initiated holding in CymaBay Therapeutics Inc. The purchase prices were between $1.41 and $4.25, with an estimated average price of $2.86. The stock is now traded at around $5.93. The impact to a portfolio due to this purchase was 4.97%. The holding were 1,599,958 shares as of .

Foresite Capital Management III, LLC added to a holding in Blueprint Medicines Corp by 46.91%. The purchase prices were between $57.09 and $79.27, with an estimated average price of $67.44. The stock is now traded at around $74.12. The impact to a portfolio due to this purchase was 5.53%. The holding were 249,598 shares as of .

Foresite Capital Management III, LLC added to a holding in Epizyme Inc by 39.85%. The purchase prices were between $13.68 and $20.46, with an estimated average price of $17.45. The stock is now traded at around $12.67. The impact to a portfolio due to this purchase was 4.06%. The holding were 998,278 shares as of .

Foresite Capital Management III, LLC sold out a holding in Immunomedics Inc. The sale prices were between $9.4 and $36.53, with an estimated average price of $28.93.

Foresite Capital Management III, LLC sold out a holding in Aerie Pharmaceuticals Inc. The sale prices were between $12 and $16.13, with an estimated average price of $14.79.

Foresite Capital Management III, LLC sold out a holding in Biohaven Pharmaceutical Holding Co Ltd. The sale prices were between $29.01 and $74.23, with an estimated average price of $52.75.